The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...

CEO Vas Narasimhan told the Wall Street Journal the company is searching for next-generation obesity drug candidates, even if ...

( MENAFN - Swissinfo) Swiss Pharmaceutical heavyweight Novartis said profit will rise this year as new medicines help offset competition from copycats of its best-selling drug. Core operating profit ...

Novartis’ new CEO Vas Narasimhan has said he wants to cut R&D costs by using digital tech, and has followed through by scaling up a virtual clinical trials collaboration with startup firm ...

The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market for deals to fill its drug pipeline and power sales growth into the 2030s, ...

Novartis CEO Vas Narasimhan said: "I would like to thank Liz for her leadership and her contributions to our business and our patients this past year. She made a significant positive impact on the ...

Novartis CEO 'very confident' on sales target, doesn't fear patent cliff Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview ...

Novartis CEO 'very confident' on sales target, doesn't fear patent cliff Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview ...

While the political pushback to ESG continues to grow in the U.S., there was little sign in Davos last week that business ...

In mid-2024, the commercial president of Pfizer’s oncology unit Suneet Varma announced his retirement after 15 years with the ...

The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...